FIELD: biotechnology.
SUBSTANCE: disclosed are monoclonal antibodies against protein 1 of programmable cell death (PD-1). Antibodies can block the binding of PD-1 ligands to PD-1 and thereby block the inhibitory function of PD-1 ligands on PD-1 expressing T-cells. Invention also relates to production and use of said antibodies.
EFFECT: invention provides effective agents for treating a variety of cancers by modulating human immune functions.
27 cl, 17 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| BISPECIFIC ANTIBODY | 2019 |
|
RU2796019C2 |
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
